---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-037096"
form_type: "8-K"
ticker: "AQST"
cik: "0001398733"
company_name: "Aquestive Therapeutics, Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T19:25:19.351239+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aquestive Q3 revenue beats; raises 2023 guidance to $47-50M; net loss narrows to $2.0M

## Summary
- Total Q3 revenue $13.0M vs $11.5M YoY; adjusted for Sympazan out-license, revenue up 42% to $13.0M from $9.2M.
- Net loss narrowed to $2.0M ($0.03/share) from $12.5M ($0.23/share); non-GAAP adjusted EBITDA loss improved to $1.3M from $7.7M.
- Full-year 2023 revenue guidance raised to $47-50M (prior $44-48M); non-GAAP adjusted EBITDA loss guidance improved to $14-17M (prior $19-22M).
- Issued $45M 13.5% Senior Secured Notes due 2028, redeeming prior 12.5% notes, resulting in ~$28M cash savings through June 2025.
- Anaphylm pivotal PK study on track for Q4 2023 start with topline data Q1 2024; Libervant NDA for ages 2-5 has PDUFA date April 28, 2024.

## SEC filing metadata
- accession: 0001628280-23-037096
- form_type: 8-K
- ticker: AQST
- cik: 0001398733
- company_name: Aquestive Therapeutics, Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1398733/000162828023037096/0001628280-23-037096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1398733/000162828023037096/aqst-20231106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-037096
- JSON: https://secwatch.observer/filing/0001628280-23-037096.json
- Plain text: https://secwatch.observer/filing/0001628280-23-037096.txt

## Key facts
- Earnings Releases
  Aquestive Therapeutics, Inc. updated its the third quarter ended September 30, 2023 guidance (raised).
  - Period: the third quarter ended September 30, 2023
  - Guidance: raised
  - Result: reported results
  source text: On November 6, 2023, Aquestive Therapeutics, Inc. (the "Company") issued a press release announcing its reported financial results for the third quarter ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1398733/000162828023037096/0001628280-23-037096-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.